NCT05327504 Written Exposure Therapy for Veterans With SUD and PTSD
| NCT ID | NCT05327504 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Substance Use Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 170 participants |
| Start Date | 2022-09-26 |
| Primary Completion | 2027-05-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 170 participants in total. It began in 2022-09-26 with a primary completion date of 2027-05-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed project will evaluate the efficacy of written exposure therapy (WET) among Veterans engaged in substance use disorder (SUD) treatment, who present with co-occurring posttraumatic stress disorder (PTSD). While SUD treatment programs traditionally do not address PTSD, effective trauma treatments have been used successfully among those with substance use comorbidities. WET is a brief trauma-focused intervention shown to effectively treat PTSD. In a recent acceptability and feasibility pilot study among Veterans with co-occurring SUD and PTSD, results showed a decrease in PTSD symptoms among participants receiving WET. The goal of the present study is to improve outcomes for Veterans who present for SUD treatment with comorbid SUD/PTSD.
Eligibility Criteria
Inclusion Criteria: * Veterans ages 18 years old or older; * Meets DSM-5 criteria for at least one substance use disorder (SUD); * Meets DSM-5 criteria for PTSD; * Approved for SUD treatment at VA Connecticut Healthcare System. Exclusion Criteria: * Veterans who meet current criteria for schizophrenia, schizophrenia-type disorders, or unmedicated mania or bipolar disorder as determined by QuickSCID-5; * current suicidal or homicidal risks necessitating a higher level of care; * Veterans who have received an Evidence-Based Psychotherapy for PTSD protocol within the past 6 months; * Problems that would prevent a participant from completing the writing intervention or study assessments (e.g., illiteracy). To assess for literacy, participants will read parts of the consent out loud.
Contact & Investigator
Sarah Meshberg-Cohen, PhD MS BS
PRINCIPAL INVESTIGATOR
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
Frequently Asked Questions
Who can join the NCT05327504 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Substance Use Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05327504 currently recruiting?
Yes, NCT05327504 is actively recruiting participants. Contact the research team at Vera.Bici@va.gov for enrollment information.
Where is the NCT05327504 trial being conducted?
This trial is being conducted at West Haven, United States.
Who is sponsoring the NCT05327504 clinical trial?
NCT05327504 is sponsored by VA Office of Research and Development. The principal investigator is Sarah Meshberg-Cohen, PhD MS BS at VA Connecticut Healthcare System West Haven Campus, West Haven, CT. The trial plans to enroll 170 participants.